• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

流感和 COVID-19 病毒与动脉粥样硬化风险的关联:荟萃分析研究和系统评价。

Association between Influenza and COVID-19 Viruses and the Risk of Atherosclerosis: Meta-Analysis Study and Systematic Review.

机构信息

Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan 6517838738, Iran.

Department of Microbiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan 6517838636, Iran.

出版信息

Adv Respir Med. 2022 Aug 12;90(4):338-348. doi: 10.3390/arm90040043.

DOI:10.3390/arm90040043
PMID:36004963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9717337/
Abstract

There is a lot of evidence to suggest that patients infected with the COVID-19 and influenza viruses are at risk of atherosclerosis. Additionally, there are heterogeneous studies on the risk of arthrosclerosis in patients infected with the influenza and COVID-19 viruses. We conducted a case−control and cross-sectional study and examined the association between the risk of atherosclerosis, and influenza virus (IV-A and IV-B) and COVID-19 infections in this study. We searched for keywords such as influenza virus, COVID-19 and atherosclerosis in English and Persian in well-known databases such as PubMed, SID, Magiran and Google Scholar. In this study, we analyzed the information using a meta-analysis, the random effect model, the I2 index and STAT (version 11.2). The results from the analysis of ten studies on influenza virus and nine studies on COVID-19 reviewed individually (totaling 6428 samples for influenza virus infections and 10,785 samples for COVID-19 infections) demonstrated a risk of arthrosclerosis in patients with influenza and COVID-19 infections, with an OR (odds ratio) = 0.45 ((95% CI): 0.25 to 0.64) and an OR (odds ratio) = 1.04 ((95% CI): 0.82 to 1.26), respectively. The present study provides new insights into the risk of atherosclerosis in patients infected with the COVID-19 and influenza viruses. Therefore, it seems necessary to consider different strategies for managing and eradicating viral infections among individuals.

摘要

有大量证据表明,感染 COVID-19 和流感病毒的患者存在动脉粥样硬化的风险。此外,关于感染流感和 COVID-19 病毒的患者发生动脉硬化的风险存在异质性研究。我们进行了病例对照和横断面研究,并在这项研究中检查了动脉粥样硬化风险与甲型流感病毒(IV-A 和 IV-B)和 COVID-19 感染之间的关系。我们在 PubMed、SID、Magiran 和 Google Scholar 等知名数据库中以英文和波斯文搜索了流感病毒、COVID-19 和动脉粥样硬化等关键词。在这项研究中,我们使用荟萃分析、随机效应模型、I2 指数和 STAT(版本 11.2)来分析信息。对单独分析的十项流感病毒研究和九项 COVID-19 研究的结果(共分析了 6428 例流感病毒感染和 10785 例 COVID-19 感染的样本)表明,流感和 COVID-19 感染患者存在发生动脉硬化的风险,比值比(OR)分别为 0.45(95%CI:0.25 至 0.64)和 1.04(95%CI:0.82 至 1.26)。本研究为 COVID-19 和流感病毒感染患者的动脉粥样硬化风险提供了新的见解。因此,似乎有必要考虑针对个体的不同策略来管理和消除病毒感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/556d/9717337/22b7db623bad/arm-90-00043-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/556d/9717337/c4c84c683638/arm-90-00043-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/556d/9717337/f5f3e41b9e18/arm-90-00043-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/556d/9717337/34884554b53d/arm-90-00043-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/556d/9717337/22b7db623bad/arm-90-00043-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/556d/9717337/c4c84c683638/arm-90-00043-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/556d/9717337/f5f3e41b9e18/arm-90-00043-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/556d/9717337/34884554b53d/arm-90-00043-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/556d/9717337/22b7db623bad/arm-90-00043-g004.jpg

相似文献

1
Association between Influenza and COVID-19 Viruses and the Risk of Atherosclerosis: Meta-Analysis Study and Systematic Review.流感和 COVID-19 病毒与动脉粥样硬化风险的关联:荟萃分析研究和系统评价。
Adv Respir Med. 2022 Aug 12;90(4):338-348. doi: 10.3390/arm90040043.
2
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
3
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
4
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
5
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.工作场所干预措施以降低医疗机构外 SARS-CoV-2 感染的风险。
Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2.
6
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
7
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
8
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
9
Vaccines for preventing influenza in healthy children.用于预防健康儿童流感的疫苗。
Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD004879. doi: 10.1002/14651858.CD004879.pub5.
10
Non-pharmacological measures implemented in the setting of long-term care facilities to prevent SARS-CoV-2 infections and their consequences: a rapid review.长期护理机构中实施的非药物措施以预防 SARS-CoV-2 感染及其后果:快速综述。
Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD015085. doi: 10.1002/14651858.CD015085.pub2.

引用本文的文献

1
Effects of Cytokines (or Activating Factors) on Arterial Endothelial Cells.细胞因子(或激活因子)对动脉内皮细胞的影响。
Int J Mol Sci. 2025 Aug 22;26(17):8142. doi: 10.3390/ijms26178142.
2
Erectile Dysfunction and Peyronie's Disease Following a Severe Case of COVID-19: A Case Report.一例重症 COVID-19 后的勃起功能障碍和佩罗尼氏病:病例报告
Case Rep Urol. 2025 Jul 4;2025:4329786. doi: 10.1155/criu/4329786. eCollection 2025.
3
Estimated causal effects of common respiratory infections on cardiovascular risk: a meta-analysis.

本文引用的文献

1
In vitro Eradication of Pseudomonas aeruginosa Persister Cell Producers by Peganum harmala.苦豆子体外根除铜绿假单胞菌持续生存细胞的研究。
Clin Lab. 2022 Feb 1;68(2). doi: 10.7754/Clin.Lab.2021.210414.
2
An Overview of Antiviral Properties of Bacteriophages with Emphasis on the Treatment of COVID-19 Infection.噬菌体抗病毒特性概述,重点探讨其在 COVID-19 感染治疗中的应用。
Infect Disord Drug Targets. 2022;22(6):e240122200472. doi: 10.2174/1871526522666220124110547.
3
and as Two Emerging Risk Factors in Atherosclerosis: Meta-Analysis Study and Systematic Review.
常见呼吸道感染对心血管风险的因果效应估计:荟萃分析。
Open Heart. 2023 Nov 28;10(2):e002501. doi: 10.1136/openhrt-2023-002501.
4
Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review.动脉粥样硬化、心血管疾病与2019冠状病毒病:一篇叙述性综述
Biomedicines. 2023 Apr 18;11(4):1206. doi: 10.3390/biomedicines11041206.
并探讨它们作为动脉粥样硬化两种新兴风险因素的作用:荟萃分析研究和系统评价。
Infect Disord Drug Targets. 2022;22(1):e210921196697. doi: 10.2174/1871526521666210921121423.
4
A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID-19): A retrospective, multicenter, observational study.一种预测 2019 冠状病毒病(COVID-19)患者心血管并发症的新型风险评分:一项回顾性、多中心、观察性研究。
Immun Inflamm Dis. 2020 Dec;8(4):638-649. doi: 10.1002/iid3.353. Epub 2020 Sep 24.
5
Association between Cardiovascular Burden and Requirement of Intensive Care among Patients with Mild COVID-19.轻度 COVID-19 患者的心血管负担与重症监护需求之间的关联。
Cardiovasc Ther. 2020 Aug 1;2020:9059562. doi: 10.1155/2020/9059562. eCollection 2020.
6
Association of acute myocardial infarction with influenza: A nationwide observational study.急性心肌梗死与流感的相关性:一项全国性观察研究。
PLoS One. 2020 Aug 6;15(8):e0236866. doi: 10.1371/journal.pone.0236866. eCollection 2020.
7
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
8
COVID-19 with Different Severities: A Multicenter Study of Clinical Features.不同严重程度的 COVID-19:一项多中心临床特征研究。
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388. doi: 10.1164/rccm.202002-0445OC.
9
Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha.长沙 161 例新型冠状病毒病 (COVID-19) 的临床特征。
Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3404-3410. doi: 10.26355/eurrev_202003_20711.
10
T cell subsets and functions in atherosclerosis.T 细胞亚群及其在动脉粥样硬化中的功能。
Nat Rev Cardiol. 2020 Jul;17(7):387-401. doi: 10.1038/s41569-020-0352-5. Epub 2020 Mar 16.